Lonza is doubling down on US and ADC expansion with its Merck CDMO deal
Lonza’s deal to acquire almost all of Merck KGaA’s US contract development and manufacturing organisation (CDMO) network will significantly boost …
Post
-
-
FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval
The US Food and Drug Administration (FDA) has authorised Johnson & Johnson’s (J&J) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for certain …
-
MHRA champions patient voices through new policy
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has unveiled a policy to enhance the role of patients and …
-
Armada to combine with Brains Bioceutical in $750m deal
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money …
-
Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA
Alfasigma has received expanded approval from the European Commission (EC) for Jyseleca (filgotinib) to treat adult patients living with active …
-
Cordavis to stay in CVS Health after bifurcation of $117bn empire
CVS Health will keep biosimilar subsidiary Cordavis under its umbrella, after the company announced plans to split off its pharmacy …
-
Big pharma-backed T-Therapeutics snags $133m to bring TCEs to clinic
UK-based biotech T-Therapeutics has netted $133m in a Series B financing round to bring its range of first-in-class T-cell receptor …
-
Podcast: An investor’s guide to preparing your clinical data package
In recent years, the biotech financing landscape has been in a period of tumult, with ever-growing competition and shifts in …
-
Evommune signs $1.1bn licence deal with Hinova for EVO570
Evommune has secured exclusive rights outside Greater China to develop, manufacture and commercialise EVO570, an autoimmune therapy, from Hinova Pharmaceuticals …
-
PharmatrophiX and Circular partner on neurodegenerative drugs
PharmatrophiX and Circular Genomics have entered a strategic collaboration to advance blood-based circular ribonucleic acid (RNA) biomarkers in neurodegenerative drug development …
-
MSD’s non-oncology sales set to double as Keytruda faces patent cliff
Merck & Co’s (MSD) blockbuster oncology product Keytruda (pembrolizumab), which has generated over half of MSD’s total revenue in the …
-
Trump’s healthcare plans under contention after Democrats’ midterm landslide
The Democrats have gained significantly more power to contest the Trump administration’s healthcare agenda after the party won the Senate …
-
Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn
Boehringer Ingelheim has become the latest drugmaker to turn to Sino Biopharmaceutical’s research team, inking a deal worth up to …
-
AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera
Pharma giant AbbVie has committed to expanding its UK-based R&D facility in Oxford while separately penning a deal around an …
-
GEBRO and Spektus sign collaboration for ActraFlex
Austria-based GEBRO Holding and Canadian company Spektus Pharma have agreed to a global commercialisation partnership for ActraFlex, an extended-release pain …
